Biocon is currently trading at Rs. 241.80, up by 3.35 points or 1.40% from its previous closing of Rs. 238.45 on the BSE.

The scrip opened at Rs. 240.05 and has touched a high and low of Rs. 245.00 and Rs. 240.05 respectively. So far 139158 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 286.40 on 01-Dec-2022 and a 52 week low of Rs. 191.60 on 21-Mar-2023.

Last one week high and low of the scrip stood at Rs. 245.00 and Rs. 231.35 respectively. The current market cap of the company is Rs. 29036.51 crore.

The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 22.05% and 17.32% respectively.

Biocon’s subsidiary -- Biocon Biologics has successfully completed Integration of Viatris’ Biosimilar Business in 31 Countries in Europe. Following the acquisition of substantially all of the global biosimilar business of Viatris in November 2022, and the related integration of over 70 emerging market countries in July 2023 and North America in September 2023, the full transition of Viatris’ biosimilars operations to Biocon Biologics in Europe represents another significant milestone as a world-leading biosimilars company.

In Europe, Biocon Biologics portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, ophthalmology, and bone health. Serving over 5.7 M patients annually, the company is committed to providing access to high-quality therapies and solutions to patients, healthcare systems and governments across the globe. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.